We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.00 | 5,402 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 14.00 | 16.00 | 15.00 | 15.00 | 15.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 149k | -7.14M | -0.1078 | -1.39 | 9.93M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 13:34:15 | O | 400 | 15.75 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/12/2024 | 07:00 | UK RNS | Celadon Pharmaceuticals PLC Finance Update |
| 06/12/2024 | 15:40 | ALNC |  TRADING UPDATES: SDX plots AIM exit; Celadon receives funds |
| 06/12/2024 | 07:00 | UK RNS | Celadon Pharmaceuticals PLC Receipt of Subscription Proceeds |
| 18/11/2024 | 12:59 | ALNC | Celadon shares slump on little progress in financing talks |
| 18/11/2024 | 07:00 | UK RNS | Celadon Pharmaceuticals PLC Update on Financial Position |
| 04/10/2024 | 12:00 | UK RNS | Celadon Pharmaceuticals PLC Investor Site Visit – Tuesday 22 October 2024 |
| 02/10/2024 | 17:32 | ALNC | Celadon Pharmaceuticals signs sales contract with Valeos Pharma |
| 02/10/2024 | 06:00 | UK RNS | Celadon Pharmaceuticals PLC New Sales Contract with a Healthcare Company |
| 30/9/2024 | 13:07 | ALNC | EXECUTIVE CHANGES: Bank of Ireland promotes ex-Barclays exec to chair |
| 30/9/2024 | 06:05 | UK RNS | Celadon Pharmaceuticals PLC Departure of Chief Financial Officer |
Celadon Pharmaceuticals (CEL) Share Charts1 Year Celadon Pharmaceuticals Chart |
|
1 Month Celadon Pharmaceuticals Chart |
Intraday Celadon Pharmaceuticals Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 29/12/2024 | 10:09 | Celadon Pharmaceuticals Plc | 104 |
| 19/3/2023 | 16:34 | Caparo Energy | 23 |
| 10/10/2009 | 17:30 | Celsis - Sales and Profits grow | 1,036 |
| 06/6/2008 | 15:22 | Chris Evans - Biotech Guru | 1,401 |
| 04/7/2007 | 08:03 | Celsis - Bios that make money | 23 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 13:34:16 | 15.75 | 400 | 63.00 | O |
| 11:51:39 | 16.00 | 12 | 1.92 | O |
| 10:11:51 | 16.00 | 40 | 6.40 | O |
| 10:10:16 | 16.00 | 38 | 6.08 | O |
| 09:00:14 | 16.25 | 2,700 | 438.75 | UT |
| Top Posts |
|---|
Posted at 30/12/2024 08:20 by Celadon Pharmaceuticals Daily Update Celadon Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker CEL. The last closing price for Celadon Pharmaceuticals was 15p.Celadon Pharmaceuticals currently has 66,220,807 shares in issue. The market capitalisation of Celadon Pharmaceuticals is £9,933,121. Celadon Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.39. This morning CEL shares opened at 15p |
Posted at 06/12/2024 08:45 by zen12 Could be the biggest recovery stock of the year, BoD sound upbeat and think about it why would they subscribe at £1.05/share if they were going under!! |
Posted at 06/12/2024 08:31 by meek Exactly what I was thinking. Clearly they know the long term future is bright. Once they get past this period of teething problems around funding, I expect the share price to recover quickly. Great time to buy imo. |
Posted at 06/12/2024 08:20 by zen12 £1.05/share investor knows what this is worth...happy to subscribe at this price when share price is 16p...tells you all that you need to know. Very positive news. |
Posted at 23/8/2024 15:10 by citys2874 would love CEL and URU to finish top number 1 and number 2 on leaderboard today |
Posted at 23/8/2024 15:09 by citys2874 CEL up 70 percent nice |
Posted at 23/8/2024 14:41 by citys2874 check out URU could well be a tripple bagger, worth buying a few today, fab day so far for Both CEL and URU |
Posted at 13/8/2024 11:12 by firestorm911 F911 is proudly reducing the target price from 1p to 0.000911p.Good shs to short. Enjoy !! Regards, F911 RMC |
Posted at 12/8/2024 08:31 by jaknife Celadon informs the market that:1. It hasn't received all of cash from the May placing (three months after!), 2. It hasn't received the cash from the loan announced in May, and 3. It only has £48k of cash left before it's lights off time |
Posted at 03/7/2024 09:50 by jaknife talk2dubya,"Well the facilities alone are worth 60m. Nice update" I'm afraid that whomever told you that was taking advantage of your naivety. The accounts are quite clear: CEL has invested less than £3m into its "facilities", which are loss-making. JakNife |
Posted at 14/3/2023 15:42 by oakridge Some thoughts on CEL and HELD (from the HELD thread) below.(Don't forget CEL possibly need a cash injection so don't get greedy on the spike!) Oakridge14 Mar '23 - 15:20 - 480 of 481 Edit 0 1 0 News out at CEL. Great news for the cannabis space. What we can say is that CEL, or, those involved in the work around this RNS = a leaky ship! Including that big volume spike / buy a few weeks ago. Naughty! Oakridge14 Mar '23 - 15:40 - 481 of 481 Edit 0 0 0 It's important to watch the reaction at CEL, and particularly the rocket that has been put under the companies share price over recent days. The home office has now extended their license so that they can enter into commercial (non research) agreements to sell a high THC content product to third parties and are the first UK based pharmaceutical facility / cultivators in the UK to do this. They say: "Within the UK, patients prescribed medicinal cannabis are reliant on imported product, often facing lengthy delays and high costs, and by becoming a UK-based producer, Celadon is in a prime position to alleviate the issues currently faced by patients." Well, it's going to be interesting to see what price-point CEL can come in at and maintain. They've already announced that expansion into their second growing room had to delayed this year by spiralling costs we have all grown so familiar with. Their facilities are, I think, only around 10% of HELD's entire license. I'll check on that. So, whilst they may be first over the line and should be congratulated, the scale of their operations, at present, is a fraction of what HELD have been granted in Greece. CEL are also operating from a country with considerably higher costs. Current mkt cap: £265M HELD: c.£11M. HELD still have work to do, but should, all being well, be rubber stamped and selling product at around the end of Q2. AIMO ADYOR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
